about
Chimeric antigen receptor therapy for cancerPrinciples of adoptive T cell cancer therapy.Effective tumor immunization induced by cells of elevated membrane-lipid microviscosity.Lysis of primary hepatic tumours by lymphokine activated killer cells5'-structural analysis of genes encoding polymorphic antigens of chemically induced tumors.T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor.Antibody-induced changes in levels of cyclic adenosine monophosphate in leukaemic lymphocytes.Characterization of a monoclonal antibody to L1210 leukaemia.Protection against syngeneic lymphoma by a long-lived cytotoxic T-cell clone.Elimination of syngeneic sarcomas in rats by a subset of T lymphocytesEradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes.T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases.Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cellsAugmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.Antibody Therapeutics in Oncology.Progress and challenges in the vaccine-based treatment of head and neck cancers.Potential Cancer Prevention and Treatment by Silencing the Killer Cell Immunoglobulin-like Receptor Gene in Natural Killer Cells Derived from Induced Pluripotent Stem Cells.Chimeric antigen receptors: driving immunology towards synthetic biology.The clinical potential of interleukin-2.Immune guided missiles.Influence of C. parvum on the effectiveness of passive serotherapy in the control of the EL4 lymphoma in C57BL/6 mice.Radioactive (Y) upconversion nanoparticles conjugated with recombinant targeted toxin for synergistic nanotheranostics of cancer
P2860
Q27013599-DB3261F4-D0C4-466E-80B8-C30E92B23F33Q34003932-54BCE052-7F71-4158-8AF1-BAB9D2EDDCDAQ34039098-8B5F8F07-BCEA-47FB-83DD-43A75F933E7BQ34527814-02D30FCE-631A-4942-84A0-1E8FECE762BEQ34628203-EC73B912-4665-4CC4-9A8F-981F8D67288EQ34709824-FF28D4EA-D0A9-4710-961E-003968423143Q36043079-E0E58A55-DC9C-404E-9866-6151ADA75143Q36046139-1791C02F-C549-4B61-BD3C-45AC9D618FC2Q36310951-6EAA5552-EAA9-472C-AA08-F7C206F66DBFQ36344092-1C938F6B-DABE-4076-B92E-687FFE599829Q36345641-0A449264-9F48-44D9-8FD8-6777AD93770CQ36345674-40DF8B55-52D5-47CA-92E4-5E14027ACCA3Q36346300-674126F4-4169-4EB6-BE55-329CE4E7E72BQ36346369-40D89BBF-FFF2-4CEE-A116-F703234E9391Q36346766-BEF081BD-01CD-45F3-B681-8D5620F9DEF7Q36348452-CE51C38B-C085-4B62-85FD-1EEEF253B49BQ36791878-99067DC0-68BE-42C8-B014-99F6E2E2FC70Q37224926-CB6FBE94-9D7D-4023-B4C5-F68DB47CE7C8Q38790470-E1D96A04-5350-4460-ABF2-014146EA1E1BQ38884383-5D7E87E3-F944-4A98-8C3B-555A513265A5Q39550760-37541B3D-4480-4B81-A037-1F33438C1A5CQ41433857-0B31B9C4-2118-4EBD-994A-B8C506445C80Q41474725-5652D80E-23C2-48E0-B82D-136B08DC01C0Q57377867-5ED5D34B-03E0-44AB-ADF7-F12F9BD85B42
P2860
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
1977年论文
@zh
1977年论文
@zh-cn
name
Passive immunotherapy of cancer in animals and man.
@en
Passive immunotherapy of cancer in animals and man.
@nl
type
label
Passive immunotherapy of cancer in animals and man.
@en
Passive immunotherapy of cancer in animals and man.
@nl
prefLabel
Passive immunotherapy of cancer in animals and man.
@en
Passive immunotherapy of cancer in animals and man.
@nl
P1476
Passive immunotherapy of cancer in animals and man.
@en
P2093
Rosenberg SA
P304
P577
1977-01-01T00:00:00Z